Abstract：【Objective】 To investigate the relationship between plasma microRNA-26b (miR-26b) and coronary artery injury in children with Kawasaki disease. 【Methods】 A total of 106 children with Kawasaki disease admitted to our hospital from February 2018 to July 2020 (observation group) were selected and divided into injury group (n=34) and non injury group (n=72) according to the condition of coronary artery injury. At the same time, 110 healthy children in the same period were selected as the control group. The expression level of miR-26b in plasma was detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR), and the relationship between miR-26b and vascular diameter in plasma of patients was analyzed by Pearson;The predictive value of miR-26b level in plasma for coronary artery injury in children with Kawasaki disease was analyzed by drawing the receiver operating characteristic (ROC) curve. 【Results】 The expression level of miR-26b in plasma of the observation group was 0.69 ± 0.12, which was significantly higher than that of the control group (1.02 ± 0.16), and the difference was statistically significant (t=17.10, P<0.05). Pearson correlation analysis showed that there was a correlation between miR-26b in plasma and vessel diameter in the diseased group. The results showed that there was a negative correlation between miR-26b in plasma and vessel diameter (r=-0.410, P<0.05). The ROC curve showed that the area under the ROC curve of plasma miR-26b level predicting coronary artery injury in children with Kawasaki disease was 0.807 (95%CI:0.724~0.890), the cut-off value was 0.69, the sensitivity was 85.30%, and the specificity was 70.80%. 【Conclusion】 The expression of miR-26b in plasma is low in children with Kawasaki disease, and the level of miR-26b is lower in children with coronary artery injury in Kawasaki disease, which is negatively related to the diameter of blood vessels. The plasma miR-26b has certain value in predicting coronary artery injury.
朱其菲, 孙锋. 川崎病患儿血浆miR-26b水平与冠状动脉损伤的相关性[J]. 医学临床研究, 2022, 39(11): 1708-1711.
ZHU Qi-fei, SUN Feng. Correlation between Plasma miR-26b Level and Coronary Artery Injury in Children with Kawasaki Disease. JOURNAL OF CLINICAL RESEARCH, 2022, 39(11): 1708-1711.
[1] YU X,LIU X X,WANG Y C,et al.Kawasaki disease complicating bilateral facial nerve palsy and giant coronary artery aneurysms:A case report[J].Medicine,2019,98(7):e14395-e14399. [2] WENG H,PENG Y,PEI Q,et al.Decreased serum annexin a1 levels in kawasaki disease with coronary artery aneurysm[J].Pediatr Res,2020,21(4):1-5. [3] EKEN S M,CHRISTERSDOTTIR T,WINSKI G,et al.miR-29b mediates the chronic inflammatory response in radiotherapy-induced vascular disease[J].JACC Basic Transl Sci,2019,4(1):72-82. [4] FARINA F M,HALL I F,SERIO S,et al.miR-128-3p is a novel regulator of vascular smooth muscle cell phenotypic switch and vascular diseases[J].Circ Res,2020,126(12):1-25. [5] 王娟,陈丹,谭利国,等.急性冠脉综合征患者血清miR-26b、IGF-1表达水平与冠脉病变程度的相关性分析[J].热带医学杂志,2019,19(6):762-766. [6] SINGH S,JINDAL A K,PILANIA R K.Diagnosis of kawasaki disease[J].Int J Rheum Dis,2018,21(1):36-44. [7] YUTARO T,OSAMU N,YOSHIHIKO M,et al.Coronary lesions and systemic inflammatory response syndrome in kawasaki disease[J].JMA J,2019,2(1):47-54. [8] 张婷,李鑫.川崎病冠状动脉损伤的机制研究进展[J].中国综合临床,2020,36(5):477-480. [9] SUCHAROV C C,MIYAMOTO S D,GARCIA A M.Circulating microRNAs as biomarkers in pediatric heart diseases[J].Prog Pediatr Cardiol,2018,25(1):1058-1065. [10] WIESE C B,ZHONG J,XU Z Q,et al.Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis[J].Atherosclerosis,2019,282(20):121-131. [11] LI H S,GAO F,WANG X W,et al.Circulating microRNA-378 levels serve as a novel biomarker for assessing severity of coronary stenosis in patients with coronary artery disease[J].Bio Sci Rep,2019,39(5):2016-2022. [12] ICLI B,DORBALA P,FEINBERG M W.An emerging role for the miR-26 family in cardiovascular disease[J].Trends Cardiovasc Med,2014,24(6):241-248. [13] ZHANG K,ZHANG B,BAI Y,et al.E2F1 promotes cancer cell sensitivity to cisplatin by regulating the cellular DNA damage response through miR-26b in esophageal squamous cell carcinoma[J].J Cancer,2020,11(2):301-310.
2022, Vol. 39 
